Response to trifluoperazine-amobarbital in outpatients with anxiety. (A double-blind, placebo-controlled study).
D000328:Adult; D000368:Aged; D000654:Amobarbital / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011602:Psychophysiologic Disorders / Q000188:drug therapy; D014268:Trifluoperazine / Q000009:adverse effects / Q000627:therapeutic use*
D010919:Placebos; D014268:Trifluoperazine; D000654:Amobarbital